ArticleTrials2026
The impact of dexmedetomidine on postoperative delirium in obstructive sleep apnea patients (DPOD-OSA): study protocol for a prospective randomized controlled trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRecent studies suggest that patients at intermediate-high risk of obstructive sleep apnea (OSA) are at greater risk of developing postoperative delirium (POD). The administration of dexmedetomidine (DEX) is suggested to prevent POD in the normal population. However, few studies have investigated the impact of DEX on POD in OSA patients. METHODS/
designA prospective, randomized controlled trial will be conducted at a single center. Patients scheduled for elective laparoscopic surgery will be screened with the STOP-Bang questionnaire (SBQ). Patients who are intermediate-high risk for OSA (SBQ score ≥ 3) will be suggested to take a portable monitoring device for the diagnosis of OSA. Apner-Hyponea Index (AHI) values > 5/h are considered OSA. All the recruited OSA patients are randomly assigned to three treatment groups. The high dose of DEX group was treated with DEX at a loading dose of 0.5 μg/kg over 10 min followed by a maintenance dose of 0.2~0.7 μg/kg/h. The low dose of DEX group was treated with DEX at a maintenance dose of 0.5 μg/kg/h. The control group was not treated with DEX. POD was assessed using the 3-min diagnostic Confusion Assessment Method (3D-CAM) or the Confusion Assessment Method for Intensive Care Unit (CAM-ICU) for 7 consecutive days or until discharge. We used the Richmond Agitation and Sedation Scale (RASS) to assess the level of sedation and drowsiness. The primary outcome will be the occurrence of POD. The secondary outcomes include pain at rest and provoked pain during postoperative day 1-7, length of stay (LOS) and postoperative complications within 30 days. DISCUSSION: The result of this study will demonstrate whether the application of DEX could reduce the incidence of POD in OSA patients. We are of the conviction that the outcomes of this trial will afford a highly efficacious modality for preventing the occurrence of POD.
trial registrationChinese Clinical Trial Registry ChiCTR2500108088. Registered on 25 August 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.